Core Viewpoint - The announcement details the judicial auction of 23,900,000 shares held by the controlling shareholder, Hainan Huluwa Investment Development Co., Ltd., which represents 14.30% of its holdings and 5.97% of the company's total share capital [2][3]. Group 1: Auction Details - The shares will be auctioned by the Haikou Intermediate People's Court on the Taobao judicial auction platform from February 27, 2026, 10:00 AM to February 28, 2026, 10:00 AM [2][3]. - The auctioned shares have been fully pledged and are currently frozen [2][3]. Group 2: Shareholder Information - As of the announcement date, Hainan Huluwa Investment holds a total of 167,079,000 shares, accounting for 41.76% of the company's total share capital, with 97,200,000 shares pledged, representing 58.18% of its holdings [6]. - If the auction is successful, Hainan Huluwa Investment's shareholding will decrease to 143,179,000 shares, reducing its ownership percentage to 35.79% [6]. Group 3: Impact on Company Control - The auction will not result in a change of control for the company, nor will it significantly impact the company's daily operations [2][6]. - The buyer of the auctioned shares will be restricted from selling them for six months following the acquisition [2][7].

Core Viewpoint - ST HULUWA (605199) announced that its controlling shareholder, Hainan Huluwa Investment Development Co., Ltd., will have 23.9 million shares auctioned through a judicial auction on Taobao from February 27, 2026, to February 28, 2026. Additionally, the company learned that the Shandong Province Qingdao City Shinan District People's Court has accepted the bankruptcy reorganization application of its controlling shareholder, Shandong Lujin Import and Export Group Co., Ltd., and indirect controlling shareholder, Xinhua Jin Group Co., Ltd. [1] Group 1 - The controlling shareholder Hainan Huluwa Investment Development Co., Ltd. holds 23.9 million shares of the company [1] - The judicial auction will take place on Taobao from February 27, 2026, to February 28, 2026 [1] - The Shandong Province Qingdao City Shinan District People's Court has accepted the bankruptcy reorganization application of Shandong Lujin Import and Export Group Co., Ltd. and Xinhua Jin Group Co., Ltd. [1]

证券代码：605199 证券简称：ST 葫芦娃 公告编号：2026-005 海南葫芦娃药业集团股份有限公司 关于控股股东部分股份被司法拍卖的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: 本次将被司法拍卖的股份为公司控股股东海南葫芦娃投资发展有限公司（以 下简称"葫芦娃投资"）持有海南葫芦娃药业集团股份有限公司（以下简称"公司" 或"葫芦娃"） 23,900,000 股股份，占其持股 14.30%，占公司总股本 5.97%。前述 股份已全部质押并被司法冻结。 前述葫芦娃投资持有的公司 23,900,000 股股份将由海南省海口市中级人民 法院于淘宝网司法拍卖网络平台进行司法拍卖，拍卖时间为 2026 年 2 月 27 日 10 时 至 2026 年 2 月 28 日 10 时止（延时的除外）。 根据《上海证券交易所上市公司自律监管指引第 15 号—股东及董事、高级 管理人员减持股份》第十四条及第二十二条的规定，本次司法拍卖股份，受让方在 受让后 6 个月内，不得减持其所受让的股份。 根据海南省海口市 ...

Core Viewpoint - The company ST HuLuWa announced that its controlling shareholder, Hainan HuLuWa Investment Development Co., Ltd., will auction 23.9 million shares, representing 14.30% of its holdings and 5.97% of the company's total share capital, through a judicial auction on Taobao from February 27 to February 28, 2026. The auction will not result in a change of control for the company and is not expected to significantly impact its daily operations and management [1]. Group 1 - The controlling shareholder will auction 23.9 million shares [1] - The shares represent 14.30% of the shareholder's holdings and 5.97% of the total share capital [1] - The auction is scheduled for February 27 to February 28, 2026, on Taobao [1] Group 2 - The auction will not lead to a change in company control [1] - There will be no significant adverse impact on the company's daily operations and management [1]

Group 1 - Lichong Group expects a net profit of 830 million to 870 million yuan for 2025, representing a year-on-year growth of 17.38% to 23.04% [1] - Shandong Zhanggu anticipates a net profit of 72 million to 80 million yuan for 2025, with a year-on-year increase of 0.65% to 11.83% [2] - Yinglian Co. forecasts a net profit of 32 million to 42 million yuan for 2025, marking a turnaround from a loss of 39.67 million yuan in the previous year [3] Group 2 - Hangya Technology announces plans for shareholders to reduce their holdings by up to 2.76% of the company's shares [4] - Guizhou Tire plans to invest in a project in Morocco to produce 6 million semi-steel radial tires annually, with a total investment of 299 million USD [5] - Laisentongling's shareholder plans to reduce their stake by no more than 1% [6] Group 3 - ST Yifei's shareholder intends to reduce their holdings by up to 1.53% [7] - Hengyi Petrochemical has fully launched the second phase of its Brunei refining project, aiming for a production capacity of 12 million tons per year [8] - Zai Sheng Technology's controlling shareholder has terminated an agreement to transfer part of the company's shares [9] Group 4 - Sry New Materials proposes a cash dividend of 0.4 yuan per 10 shares for the first three quarters of 2025 [10] - Quanyin High-Tech announces that the offer period for China Seed Group's acquisition has expired, leading to a temporary suspension of its stock [11] - Zhonggang Luonai's shareholder plans to reduce their stake by up to 1% [12] Group 5 - Nanmo Bio expects to receive a government subsidy of 5.8 million yuan for its subsidiary [13] - Beite Technology has received approval from the China Securities Regulatory Commission for a stock issuance to specific investors [14] - Qianyuan Pharmaceutical's subsidiary has obtained drug registration certificates for a new medication [15] Group 6 - Boto Integrated plans to reduce its holdings by no more than 1% [16] - Wanze Co. intends to reduce its stake by up to 1.66% [17] - Tianci Materials will halt production for maintenance on its lithium hexafluorophosphate production line starting March 1, 2026 [18] Group 7 - Haopeng Technology plans to raise up to 800 million yuan through a private placement [20] - Yisheng Co. reports a 43.32% year-on-year increase in sales revenue for its white feather broiler chicks in December 2025 [21] - Jinyu Medical proposes a cash dividend of 8.8 yuan per 10 shares for the first three quarters of 2025 [22] Group 8 - Caesar Travel's subsidiary has won a management service project for the Qingdao International Cruise Port [23] - Kelun Pharmaceutical plans to repurchase shares worth 50 million to 100 million yuan [24] - Jiangling Motors reports a 10.56% year-on-year increase in cumulative sales for 2025 [25] Group 9 - Yilian Technology plans to issue convertible bonds to raise up to 1.2 billion yuan [26] - Shaanxi Guotou A intends to participate in a capital increase for Chang'an Bank, with an amount not exceeding 800 million yuan [27] - Oupokang Vision has obtained a production license for eye drops [28] Group 10 - Shanghai Electric plans to provide management services for overseas assets of China Electric International [30] - Yingfang Micro is planning a major asset restructuring, leading to a temporary suspension of its stock [31] - Victory Energy's stock will resume trading after completing a verification process [32] Group 11 - China Merchants Industry has signed a shipbuilding agreement with Dalian Shipbuilding [33] - Kunyu Group has appointed a new chairman following a board meeting [34] - Microchip Bio's clinical trial application for a new diabetes treatment has been accepted [35] Group 12 - Hanshuo Technology has signed a sales intention agreement for smart shopping carts with Woolworths in Australia [36] - Zhongmin Energy's three photovoltaic power station projects have been included in the Fujian Province development list [37] - Penghui Energy plans to issue H-shares and apply for listing on the Hong Kong Stock Exchange [38] Group 13 - Victory Energy reports that the acquirer has deposited a guarantee for the acquisition [39] - Fangsheng Pharmaceutical proposes a special dividend of 0.15 yuan per share for 2025 [40] - Nanning Department Store has received approximately 14.28 million yuan in government subsidies since January 2025 [41] Group 14 - Jushen Co. has signed a bauxite transfer agreement with a company in Guinea [42] - ST Huluwawa has received a drug registration certificate for a new inhalation solution [43] - Zhongzhi Co. will become the controlling shareholder following a share transfer agreement [44] Group 15 - Chuangli Group has signed a strategic cooperation framework agreement with Chuanjiu Construction [45]

ST葫芦娃（605199）(605199.SH)发布公告，公司近日收到国家药品监督管理局(简称"国家药监局")核准 签发的关于盐酸左沙丁胺醇雾化吸入溶液的《药品注册证书》。盐酸左沙丁胺醇雾化吸入溶液适用于治 疗或预防成人及6岁以上儿童可逆性气道阻塞性疾病引起的支气管痉挛。 ...

Core Viewpoint - ST Huluwawa (605199.SH) has received approval from the National Medical Products Administration for the drug registration certificate of Salbutamol Hydrochloride Nebulization Solution, which is intended for the treatment or prevention of bronchospasm caused by reversible airway obstructive diseases in adults and children over 6 years old [1] Company Summary - The approval of Salbutamol Hydrochloride Nebulization Solution marks a significant milestone for ST Huluwawa, expanding its product offerings in the respiratory treatment market [1] - This product is specifically designed to address bronchospasm, indicating a focus on respiratory health and potential growth in this therapeutic area [1] Industry Summary - The approval aligns with the increasing demand for effective treatments for respiratory conditions, particularly in the context of an aging population and rising prevalence of respiratory diseases [1] - The introduction of this nebulization solution may enhance competition within the respiratory drug market, potentially impacting market dynamics and pricing strategies [1]

证券代码：605199 证券简称：ST 葫芦娃 公告编号：2026-004 海南葫芦娃药业集团股份有限公司 关于获得盐酸左沙丁胺醇雾化吸入溶液 药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 海南葫芦娃药业集团股份有限公司（以下简称"公司"）近日收到国家药品监督 管理局（以下简称"国家药监局"）核准签发的关于盐酸左沙丁胺醇雾化吸入溶液 的《药品注册证书》。现将有关情况公告如下： 一、药品基本情况 药物名称：盐酸左沙丁胺醇雾化吸入溶液 剂型：吸入制剂 注册分类：化学药品 3 类 规格：3ml：0.63mg（按 C₁₃H₂₁NO₃计） 上市许可持有人：海南葫芦娃药业集团股份有限公司 受理号：CYHS2302228 药品批准文号：国药准字 H20256401 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品符 合药品注册的有关要求，批准注册，发给药品注册证书。 二、药品研发及相关 盐酸左沙丁胺醇雾化吸入溶液适用于治疗或预防成人及 6 岁以上儿童可逆性气 道阻塞性疾病引起的支气管痉挛。 盐酸左沙丁 ...

葫芦娃公告称，近日收到国家药监局核准签发的盐酸左沙丁胺醇雾化吸入溶液《药品注册证书》。该药 品为吸入制剂，适用于治疗或预防成人及6岁以上儿童支气管痉挛。原研制剂未在国内上市，获批后视 同通过仿制药一致性评价，除该公司外国内还有22家企业获批准文号。公司对该产品累计投入研发费用 570.97万元。不过，药品销售业绩存在不确定性。 ...

近日，海南省工商联在海口召开"2025海南民营企业100强及研发投入20强"发布会。葫芦娃药业集团一 举斩获2025海南民营企业100强第34位及研发投入20强第5位，成为海南医药行业在自贸港政策下创新突 破的生动缩影。 智能制造：打造行业标杆 集团美安儿童药智能制造基地于2024年投产，引入国际先进设备与智能管理系统，建成涵盖片剂、胶囊 剂、颗粒剂、口溶膜剂等药品制剂生产线，实现生产全流程自动化、信息化。通过实施WCM精益生产 项目和数字仓储系统，产能与人均效能显著提升，成功入选海南省工业互联网应用优秀案例与数字化转 型样本企业，成为医药行业智能化转型标杆。 未来展望：锚定"十五五"，与自贸港共成长 面向"十五五"规划开局之年，葫芦娃药业集团将依托自贸港"零关税""低税率"等政策红利，充分把握封 关运作带来的开放优势，持续深化科技创新与智能制造的融合发展，加速推进创新药产业化进程。与此 同时，集团将积极开拓东南亚、中东等海外市场，推动"海南制造"走向国际舞台，致力于成为中国儿童 健康全生命周期的守护者，为海南自贸港建设贡献坚实的医药力量！ 作为扎根海南的儿药领军企业，葫芦娃药业集团坚持以"健康中国娃"为企业 ...